ANAB: financial statements from SEC — TradeAlmanac

ANAB

AnaptysBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	26m	76m	22m	28m	30m	11m
Research and development	—	31m	38m	41m	42m	42m
Selling, general and administrative	26m	10m	11m	14m	11m	9m
Operating expenses	60m	42m	48m	55m	53m	51m
Operating income	−35m	35m	−26m	−28m	−23m	−40m
Pre-tax income	−53m	15m	−39m	−39m	−33m	−47m
Income tax	40,000	0	39,000	44,000	0	9,000
Net income	−53m	15m	−39m	−39m	−33m	−47m
Earnings per share	−1.84	0.54	−1.34	−1.28	−1.14	−1.71
Earnings per share, diluted	−1.84	0.52	−1.34	−1.28	−1.14	−1.71
Weighted average shares	29m	28m	29m	31m	29m	27m
Weighted average shares, diluted	29m	29m	29m	31m	29m	27m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	248m	238m	110m	44m	99m	123m	192m	72m
Receivables	26m	34m	76m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−26m	−11m
Depreciation and amortisation	130,000	146,000
Share-based compensation	14m	9m
Capital expenditure	17,000	35,000
Investing cash flow	35m	15m
Share buybacks	0

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)